Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials

OBJECTIVES: To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE. METHODS: A post hoc analysis was conducted using pooled data from phase III, randomised, 52-week, placebo-controlled, Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruce, Ian N, van Vollenhoven, Ronald F, Psachoulia, Konstantina, Lindholm, Catharina, Maho, Emmanuelle, Tummala, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Lupus Nephritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843193/
https://www.ncbi.nlm.nih.gov/pubmed/36639192
http://dx.doi.org/10.1136/lupus-2022-000761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843193/
https://www.ncbi.nlm.nih.gov/pubmed/36639192
http://dx.doi.org/10.1136/lupus-2022-000761

Ejemplares similares